Piramal, Aji Bio-Pharma Partner to Support ADC Development & Manufacturing

Piramal Pharma Solutions, a global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., and Ajinomoto Bio-Pharma Services, a provider of biopharmaceutical manufacturing services and platform technologies, have announced a strategic collaboration.

Under this collaboration, Piramal will refer applicable customers seeking ADC manufacturing technology to Aji Bio-Pharma and AJICAP. Meanwhile, Aji Bio-Pharma will refer Piramal to customers as a potential CDMO for manufacturing products using AJICAP technology, supporting their programs across development and manufacturing.

Following the execution of this agreement, Piramal and Ajinomoto will enter into a separate Material Transfer Agreement (MTA) to allow the transfer of technology between companies. The MTA will equip Piramal with the expertise, capabilities, and personnel for it to manufacture AJICAP-based products with precision and speed.

Ajinomoto’s AJICAP technology facilitates the development of site-specific ADCs and linker technologies through simple, efficient processes, empowering early-stage pharmaceutical developers to create ADCs with higher efficacy and lower toxicity. Pairing this innovative platform with Piramal’s clinical and commercial ADC GMP manufacturing expertise enables customers to accelerate development, streamline tech transfer, and simplify scale-up.

By combining AJICAP’s site-specific conjugation technology with Piramal’s development and manufacturing expertise, this collaboration aims to help customers deliver safe, effective, and precise ADC therapies with exceptional efficiency.

“We are excited to collaborate with Ajinomoto Bio-Pharma Services and enhance our ADC platform by offering manufacturing support for AJICAP-based products,” said Peter DeYoung, CEO, Piramal Global Pharma. “With the implementation of these capabilities, we will accelerate innovation and expand access to this technology for our customers and their patients worldwide.”

“This collaboration with Piramal expands the ecosystem supporting AJICAP technology by connecting licensed customers with an experienced ADC manufacturing partner,” said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. “Through this collaboration, we aim to provide our customers with streamlined pathways and access to deep ADC expertise to advance high-quality programs from early development through commercial manufacturing.”